Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects. Issue 3 (June 2015)

• Record Type: Journal Article
• Authors: Tomaru, Atsuko; Takeda-Morishita, Mariko; Maeda, Kazuya; Banba, Hirokazu; Takayama, Kozo; Kumagai, Yuji; Kusuhara, Hiroyuki; Sugiyama, Yuichi
• Is Part Of: Drug metabolism and pharmacokinetics. Volume 30:Issue 3(2015)
• Page Start: 221
• Page End: 226
• Publication Date: 2015-06
• Subjects: Saquinavir -- Fexofenadine -- Cremophor EL -- P-gp -- Oral absorption; Drugs -- Metabolism -- Periodicals; Pharmacokinetics -- Periodicals; 615.7
• DOI: 10.1016/j.dmpk.2015.01.002
• Languages: English
• ISSNs: 1347-4367

Abstract

Abstract: Modulation of CYP3A and/or P-gp function by several excipients has been reported. However, relatively few studies have investigated their effects in humans. Therefore, the aim of this clinical study was to clarify the effects of Cremophor EL on the inhibition of CYP3A and P-gp in the human small intestine. Eight healthy Japanese subjects received an oral dose of saquinavir (2 mg, substrate of P-gp/CYP3A) or fexofenadine (50 μg, substrate of P-gp) without or with Cremophor EL (720 mg and 1440 mg). Significant increases in Cmax (1.3-fold) and AUC0–24 (1.6-fold) were observed for fexofenadine when administered with 1440 mg of Cremophor EL. In contrast, a significant decrease was observed for saquinavir when administered with 720 mg of Cremophor EL. The equilibrium dialysis experiment was performed to investigate the micellar interaction between Cremophor EL and drugs. The equilibrium dialysis study showed that saquinavir was far extensively entrapped into the micelles. The reduced concentration of free saquinavir by entrapping in micelles was considered to cause the reduction of systemic exposure for saquinavir. In conclusion, this clinical study suggests that Cremophor EL at least inhibits P-gp in the human small intestine. Graphical abstract: